Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
HonorHealth Research Institute
iOnctura
Ruijin Hospital
Centre Oscar Lambret
Federation Francophone de Cancerologie Digestive
Ohio State University Comprehensive Cancer Center
University of California, San Diego
Next Biomedical Co., Ltd.
Cardiovascular and Interventional Radiological Society of Europe
Centre Hospitalier Universitaire de Nīmes
Centre Paul Strauss
Tongji University
Institut National de la Santé Et de la Recherche Médicale, France
Abramson Cancer Center at Penn Medicine
Hospices Civils de Lyon
University of Kentucky
Institut National de la Santé Et de la Recherche Médicale, France
Vedanta Biosciences, Inc.
Eisai Inc.
National Cancer Institute (NCI)
Ramsay Générale de Santé
Cook Group Incorporated
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Incyte Corporation
Novartis
Incyte Corporation
Trishula Therapeutics, Inc.
University of Michigan Rogel Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Azienda Ospedaliero-Universitaria di Modena
Mirror Biologics, Inc.
ImmunoGenesis
Esperas Pharma Inc.
Zhejiang University
Imugene Limited
Mirati Therapeutics Inc.
Samsung Medical Center
Memorial Sloan Kettering Cancer Center
Cedars-Sinai Medical Center
Boehringer Ingelheim
PureTech
National Cancer Institute (NCI)
Viome
Institut Sainte Catherine
Washington University School of Medicine
National Taiwan University Hospital
Centre Hospitalier Universitaire de Besancon
Symphogen A/S
Acepodia Biotech, Inc.